Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

RALTEGRAVIR POTASSIUM

RALTEGRAVIR POTASSIUM

Standard Dose
EQ 400MG BASE
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview RALTEGRAVIR POTASSIUM is listed in Drugs@FDA under application 203540 (ANDA).

Marketing status: Discontinued Active ingredient RALTEGRAVIR POTASSIUM Form and strength TABLET;ORAL - EQ 400MG BASE Sponsor HETERO LABS LTD III Submission history Latest submission status date: 2024-12-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview RALTEGRAVIR POTASSIUM is listed in Drugs@FDA under application 203540 (ANDA). Marketing status: Discontinued Active ingredient RALTEGRAVIR POTASSIUM Form and strength TABLET;ORAL - EQ 400MG BASE Sponsor HETERO LABS LTD III Submission history Latest submission status date: 2024-12-19 00:00:00. Submission type: ORIG.

Monitoring

  • • Review priority: STANDARD
  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.